APA (7th ed.) Citation

Landsburg, D. J., Barta, S. K., Ramchandren, R., Batlevi, C., Iyer, S., Kelly, K., . . . Oki, Y. (2021). Fimepinostat (CUDC‐907) in patients with relapsed/refractory diffuse large B cell and high‐grade B‐cell lymphoma: Report of a phase 2 trial and exploratory biomarker analyses. British journal of haematology, 195(2), 201-209. https://doi.org/10.1111/bjh.17730

Chicago Style (17th ed.) Citation

Landsburg, Daniel J., et al. "Fimepinostat (CUDC‐907) in Patients with Relapsed/refractory Diffuse Large B Cell and High‐grade B‐cell Lymphoma: Report of a Phase 2 Trial and Exploratory Biomarker Analyses." British Journal of Haematology 195, no. 2 (2021): 201-209. https://doi.org/10.1111/bjh.17730.

MLA (9th ed.) Citation

Landsburg, Daniel J., et al. "Fimepinostat (CUDC‐907) in Patients with Relapsed/refractory Diffuse Large B Cell and High‐grade B‐cell Lymphoma: Report of a Phase 2 Trial and Exploratory Biomarker Analyses." British Journal of Haematology, vol. 195, no. 2, 2021, pp. 201-209, https://doi.org/10.1111/bjh.17730.